PubRank

M I Lorber

Author PubWeight™ 64.09‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cloned T lymphocytes and monoclonal antibodies as probes for cell surface molecules active in T cell-mediated cytolysis. Immunol Rev 1982 3.06
2 In vivo formation of complex microvessels lined by human endothelial cells in an immunodeficient mouse. Proc Natl Acad Sci U S A 2000 2.67
3 Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature 2000 2.55
4 A clone-specific monoclonal antibody that inhibits cytolysis of a cytolytic T cell clone. J Exp Med 1983 1.48
5 Ranitidine, cimetidine, and the cyclosporine-treated recipient. Transplantation 1986 1.44
6 A novel united network for organ sharing region kidney allocation plan improves transplant access for minority candidates. Transplantation 1999 1.37
7 Factors affecting the waiting time of cadaveric kidney transplant candidates in the United States. JAMA 1992 1.35
8 A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007 1.23
9 I-A antigens on cloned alloreactive murine T lymphocytes are acquired passively. J Immunol 1982 1.23
10 Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras. Nat Biotechnol 1997 1.20
11 Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997 1.19
12 Strategies for success in academic surgery. Surgery 1995 1.17
13 Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. Transplantation 1987 1.13
14 Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995 1.09
15 Renal transplant protection during abdominal aortic aneurysmectomy with a pump-oxygenator. Surgery 1981 1.06
16 Hepatic retransplantation in New England--a regional experience and survival model. Transplantation 1993 1.01
17 Pleurotomy, pneumothorax, and surveillance during living donor nephroureterectomy. Urology 1998 0.99
18 Complications of cyclosporine-prednisone immunosuppression in 402 renal allograft recipients exclusively followed at a single center for from one to five years. Transplantation 1987 0.94
19 Breast feeding and maternal-donor renal allografts. Possibly the original donor-specific transfusion. Transplantation 1984 0.94
20 Liver transplantation for hepatoblastoma. The American experience. Ann Surg 1991 0.94
21 Complications in cardiac transplant patients requiring general surgery. Surgery 1988 0.92
22 Dermal microvascular injury in the human peripheral blood lymphocyte reconstituted-severe combined immunodeficient (HuPBL-SCID) mouse/skin allograft model is T cell mediated and inhibited by a combination of cyclosporine and rapamycin. Am J Pathol 1998 0.91
23 Successful transplantation of cyclosporine-treated allograft recipients with serologically positive historical, but negative preoperative, donor crossmatches. Transplantation 1985 0.89
24 100 living-related kidney donor evaluations using digital subtraction angiography. Transplantation 1985 0.89
25 Multicenter evaluation of a polyurethaneurea vascular access graft as compared with the expanded polytetrafluoroethylene vascular access graft in hemodialysis applications. J Vasc Surg 2001 0.88
26 The immunochemical distribution of cyclophilin in normal mammalian tissues. Transplantation 1991 0.87
27 Multivariate analysis of risk factors impacting on immediate and eventual cadaver allograft survival in cyclosporine-treated recipients. Transplantation 1987 0.85
28 Unusual causes of increased vascular impedance in renal transplants: duplex Doppler evaluation. Radiology 1988 0.85
29 Human T cells infiltrate and injure pig coronary artery grafts with activated but not quiescent endothelium in immunodeficient mouse hosts. Transplantation 2001 0.84
30 Investigation of HTLV-3 serology in a renal transplant population. Transplantation 1987 0.83
31 The evolving experience using everolimus in clinical transplantation. Transplant Proc 2004 0.83
32 Clinical relevance of anti-HLA antibodies pre and post transplant. Am J Med Sci 1997 0.83
33 A three-year experience with serum anodal trypsinogen as a biochemical marker for rejection in pancreatic allografts. False positives, tissue biopsy, comparison with other markers, and diagnostic strategies. Transplantation 1992 0.83
34 Inhibition of proliferation of MIs- and Ia-reactive cloned T cells by a monoclonal antibody against a determinant shared by I-A and I-E. J Immunol 1983 0.83
35 Incidence, timing and site of infections among pancreas transplant recipients. J Hosp Infect 2004 0.82
36 Cyclosporine toxicity: the effect of combined therapy using cyclosporine, azathioprine, and prednisone. Am J Kidney Dis 1987 0.81
37 Analysis of pharmacokinetic profiles in 232 renal and 87 cardiac allograft recipients treated with cyclosporine. Transplant Proc 1986 0.81
38 FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter study. Clin Transplant 2009 0.81
39 T cell subset patterns in cyclosporine-treated renal transplant recipients with primary cytomegalovirus disease. Transplantation 1987 0.81
40 Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 1986 0.81
41 Pig but not human interferon-gamma initiates human cell-mediated rejection of pig tissue in vivo. Proc Natl Acad Sci U S A 1997 0.80
42 Sirolimus-based immunosuppression with reduce dose cyclosporine or tacrolimus after renal transplantation. Transplant Proc 2003 0.79
43 Complications of cyclosporin therapy. World J Surg 1986 0.79
44 RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation 2001 0.79
45 Influence of breast feeding on subsequent reactivity to a related renal allograft. J Surg Res 1984 0.79
46 Human TNF can induce nonspecific inflammatory and human immune-mediated microvascular injury of pig skin xenografts in immunodeficient mouse hosts. J Immunol 2000 0.79
47 Temporal changes of cytokines and nitric oxide products in urine from renal transplant patients. Kidney Int 2000 0.79
48 Effects of H2-receptor antagonists on renal function in cyclosporine-treated renal transplant patients. Transplantation 1989 0.78
49 Does cyclosporine improve the results of HLA-identical renal transplantation? Transplant Proc 1987 0.78
50 Does cyclosporine influence the results of cadaver retransplantation? Hum Immunol 1985 0.78
51 Aspergillus vertebral osteomyelitis after simultaneous kidney-pancreas transplantation. Transpl Infect Dis 2003 0.78
52 Cyclosporine--an overview of recent advances. Year Immunol 1985 0.78
53 Influence of cyclosporine on posttransplant blood pressure response. Am J Kidney Dis 1987 0.78
54 Allogeneic and xenogeneic vascular injury and protection. Transplant Proc 1998 0.77
55 The effect of cyclosporine administration on the cellular distribution and content of cyclophilin. Transplantation 1992 0.77
56 Serum sialic acid, a risk factor for cardiovascular disease, improves following pancreas transplantation. Transplant Proc 1995 0.77
57 Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients. Clin Cancer Res 1996 0.77
58 Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients. J Clin Oncol 1997 0.77
59 Nitric oxide synthase induction with renal transplant rejection or infection. Kidney Int 1996 0.77
60 Nuclear membrane-associated cyclophilins of potential importance in cyclosporine immunosuppression. Transplant Proc 1993 0.77
61 Serum markers for pancreas rejection: long-term behavior following clinical pancreatico-duodenal transplantation. Transplant Proc 1991 0.77
62 Exacerbation of cyclosporine toxicity by concomitant administration of erythromycin. Transplantation 1987 0.76
63 Peritransplant fluid collections. Ultrasound evaluation and clinical significance. Radiology 1981 0.76
64 Exposure-efficacy relationships of a fingolimod-everolimus regimen in kidney transplant patients at risk for delayed graft function. Transplant Proc 2006 0.76
65 Pancreas after kidney transplantation: HLA mismatch does not preclude success. Transplant Proc 1997 0.76
66 Comparison of five cyclosporine-prednisone regimens for induction of immunosuppression in cadaveric kidney recipients: a retrospective analysis of 245 cases. Transplant Proc 1986 0.76
67 Parameters of high bone-turnover predict bone loss in renal transplant patients: a longitudinal study. Transplantation 2001 0.76
68 Cyclophilin binding: a more accurate measure of cyclosporine immunosuppressive activity after renal transplantation. Transplant Proc 1991 0.76
69 A clone specific monoclonal antibody which inhibits T cell-mediated cytolysis. Adv Exp Med Biol 1982 0.75
70 Control of cloned alloreactive T lymphocyte proliferative responses. A possible role for cell-surface-bound alloantigen. Transplantation 1984 0.75
71 Cyclosporine, azathioprine, and prednisone as treatment for cyclosporine-induced nephrotoxicity in renal transplant recipients. Transplant Proc 1985 0.75
72 A new allocation plan for renal transplantation. Transplant Proc 1999 0.75
73 Must living renal donors be hospitalized overnight prior to surgery? Clin Transplant 1996 0.75
74 Management of immunosuppressive problems in renal allograft recipients. Transplant Proc 1987 0.75
75 Endothelial cell activation by tumor necrosis factor elicits human antiporcine cell-mediated rejection responses. Transplant Proc 2001 0.75
76 Investigation of human T-lymphotropic virus III serology in a renal transplant population. Transplant Proc 1987 0.75
77 A new allocation plan for renal transplantation. Transplantation 1999 0.75
78 A regional experience with emergency liver transplantation. Transplantation 1996 0.75
79 Body size mismatch between donor and recipient and the development of chronic rejection in renal transplantation. Transplant Proc 1997 0.75
80 Unsensitized human T cells do not infiltrate or injure quiescent pig coronary artery grafts in immunodeficient mouse hosts. Transplant Proc 2001 0.75
81 Are calcium channel blockers protective against first-dose reactions to OKT3? Transplantation 1992 0.75
82 Cyclosporine action in blockade of cellular immune responses. Year Immunol 1986 0.75
83 Etiology and management of early and late peritransplant infections. J Urol 1982 0.75
84 Clinical results of ciclosporin-prednisone therapy in renal transplantation. Contrib Nephrol 1986 0.75
85 Posttransplant Epstein-Barr virus infection is associated with elevated levels of CD19+ B lymphocytes. Transplantation 1995 0.75
86 Nucleus associated FK 506 binding proteins with potential relevance to FK 506 immunosuppression. Transplant Proc 1993 0.75
87 Immunoregulatory mechanisms in cyclosporine-treated renal allograft recipients. Transplantation 1987 0.75
88 Immunologic monitoring after organ transplantation: relationship between Epstein-Barr virus infection and CD19+ B cells measured by flow cytometry. Transplant Proc 1995 0.75
89 Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early posttransplant period. Transplant Proc 2004 0.75
90 Role of suppressor cells in cyclosporine-treated allograft recipients. Transplant Proc 1987 0.75
91 Long-term results of cyclosporine therapy in recipients of mismatched living related kidneys. Transplant Proc 1986 0.75
92 Risk factors for cadaveric donor allograft survival in cyclosporine-prednisone-treated recipients. Transplant Proc 1987 0.75
93 Predictors of rejection in cyclosporine-treated cardiac allograft recipients. Transplant Proc 1987 0.75
94 T-cell lineage of a Friend virus-induced lymphatic leukemia in athymic rats. J Natl Cancer Inst 1983 0.75
95 Serum anodal trypsinogen is a predictive biochemical marker for pancreas allograft rejection. Transplant Proc 1990 0.75